<?xml version="1.0" encoding="UTF-8"?>
<p id="par0150">PET has also been used to follow the deposition and retention of an inhaled dose of radiolabeled zanamivir, another inhibitor of the influenza viral neuraminidase, in human subjects (
 <xref rid="bib0030" ref-type="bibr">Bergstrom et al., 1999</xref>, 
 <xref rid="bib0080" ref-type="bibr">Cass et al., 1999</xref>). These studies only involved uninfected individuals, but it is evident that the same procedure could be used to track the distribution of zanamavir in persons infected with seasonal influenza viruses, either before or after treatment. Such experiments would help to determine the effect of therapy on the course of illness, and would reveal whether the radiolabeled drug could be used to detect and track the spread of virus in the respiratory tract.
</p>
